# GCPGC in Chemotherapy-induced Neutropenia

> **NCT01328938** · PHASE2,PHASE3 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 177 (actual)

## Conditions studied

- Chemotherapy Induced Neutropenia

## Interventions

- **BIOLOGICAL:** GCPGC 3.6mg
- **BIOLOGICAL:** GCPGC 6mg
- **BIOLOGICAL:** Neulasta (pegfilgrastim) 6mg
- **BIOLOGICAL:** GCPGC 6mg

## Key facts

- **NCT ID:** NCT01328938
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-11
- **Final completion:** 2013-05
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2013-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01328938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01328938, "GCPGC in Chemotherapy-induced Neutropenia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01328938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*